5ht agonists for treating disorders
AssigneeThe Regents of the University of California
InventorScott C. Baraban
Life of this patent
Estimating the term…
Abstract
Provided, inter alia, are methods for treating an epilepsy disorder using a 5HT receptor agonist, or a pharmaceutically acceptable salt thereof.
Claims18
-58. (canceled)
A method of treating Dravet syndrome, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist, wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof, and wherein said subject has a cardiovascular disease, is resistant to treatment with a serotonin reuptake inhibitor, or susceptible to side effects when administered a serotonin reuptake inhibitor.
A method of treating Ohtahara syndrome, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist, wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.
A method of treating an early myoclonic encephalopathy, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist, wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.